A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 trial of Venetoclax in multiple myeloma, run by Oncotherapeutics, now recruiting.
Overview
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06115135 by Oncotherapeutics, with 39 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-04-30. Interventions recorded: Venetoclax. Conditions listed: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Shares Venetoclax, Multiple myeloma.
- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Venetoclax, Multiple myeloma.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares Venetoclax, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Venetoclax, Multiple myeloma.
- PersonShaji K. Kumar
Shares Venetoclax, Multiple myeloma.
- TrialA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Shares Venetoclax, Multiple myeloma.
- TrialStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Shares Venetoclax, Multiple myeloma.
- TermFixed-duration vs continuous therapy
Shares Venetoclax, Multiple myeloma.